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Results. A total of 135 women with a mean age of 67 years were analyzed. The average of ﬁelds used was 4.5 (range 3–8). The
mean breast volume that received ≥95% of the prescription dose was 97.6% and 0.5% was the average of volume that received
≥107% of the prescription dose. The mean maximum dose to the breast was 46.4Gy and the mean V20 in the ipsilateral lung
was 12.4%.
Conclusion. The use of tangential ﬁelds with reduced segments is a feasible treatment that allows acceptable dosimetric outcomes
in the setting of patients with low risk breast cancer who receive hypofractionated radiotherapy. Further studies that compare
multiple ﬁelds versus IMRT are needed to know if both techniques are equiparable.
http://dx.doi.org/10.1016/j.rpor.2013.03.071
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Backgruond. Three-dimensional conformal radiotherapy (3D-CRT) in the planning treatment of locorregional breast cancer includ-
ing the internal mammary chain is realized in our centre, by using tangential ﬁelds with multisegments; and PA-AP ﬁelds for
nodal areas. Helical Tomotherapy (HT) is a sort of intensity-modulated radiation therapy, that uses an integrated CT scanner
during radiation which is performed helicoidally.
Purpose. To compare the dosimetric distribution of two breast radiotherapy plans: Three-dimensional conformal radiotherapy vs
Helical Tomotherapy.
Methods and materials. Six patients with stage IIIC breast cancer affecting internal mammary chain (clinically and/or histologically
conﬁrmed), were included in this study. For each patient, treatment plans were generated to compare de Three-dimensional con-
formal radiotherapy (3D-CRT) against the Helical Tomotherapy (HT). CT simulation was performed in supine position with both
arms above head and external rotation. The planning target volumes (PTV) included the chest wall/whole breast, supraclavicular,
axillary, and internal mammary chain nodes. Dose prescription was 50.4Gy, in 28 fractions of 1.8Gy, to the PTV.
Results. The average V20 and V5 for heart was 7.28% and 84.94% for HT vs 2.73% and 8.18% for 3D-CRT. The average V30, V20 and
V5 for ipsilateral lung was 19.66%, 31.47% and 92.61% for HT vs 33.78%, 38.41% and 54.82% for 3D-CRT. The average percentage
of the contralateral lung receiving ≥5Gy was 62.41% for HT and 2.86% for 3D-CRT. The average percentage of the contralateral
breast receiving ≥5Gy was 50.33% for HT and 8.18% for 3D-CRT.
Conclusion. Tomotherapy decreases high dose irradiation in lung at the expense of a greater volume of lung and heart receiving
low-dose irradiation and higher irradiation of contralateral breast and lung. The choice of treatment plan must be individualized
for each patient based on doses in heart, and contralateral breast and lung.
http://dx.doi.org/10.1016/j.rpor.2013.03.072
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Introduction. New accelerated hypofractionated treatments for breast irradiation are an important improvement of the conven-
tional treatment schemes that allow an early return of the patients to them previous lifestyle. The tolerance, cosmetic results,
local control and survival of these new treatments must be the same, or better, as that of conventional treatments. Objective:
Implementation of accelerated hypofractionation 40Gy in 15 sessions for mammary gland irradiation.
Material and methods. Since 2011, 50 patients have been treated with this hypofractionation schema in our institution. All patients
presented lesions smaller than 1 cm treated with conservative surgery. Exclusive mammary gland irradiation was performed
using IMRT to improve dose homogeneity. We have developed protocols to provide speciﬁc requirements in the deﬁnition of
structures, dosimetric acceptance criteria, positioning control, which includes changes in the breast volume, and speciﬁc care
treatment for toxicities prevention. Tracking of skin toxicitywas doneusing visual rating scales for its quantitative determination.
To assess the quality of life of patients we used surveys DLQI and Skindex-29.
Results. Uncertainty in the patient setup was less than 3mm. The average dose of breast PTV is greater than 98%, maximum
dose is less than 106% and D95 is greater than 95%. V20 of lung is smaller than 15%, and less than 3% for heart. Only dermatitis
grade I was detected as dermal toxicity in some patients. The DLQI surveys conducted to evaluate changes in the quality of life of
patients showed very low condition being the items on pain, burning and itching the highest. Skindex-29 showed an involvement
low or very low.
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Conclusions. Accelerated breast hypofractionation treatment allows minimizing the impact of radiation therapy on the patients
quality of life without worsening tolerance and cosmetic results. Its application, however, requires a quality improvement of the
treatments compared to the conventional procedure.
http://dx.doi.org/10.1016/j.rpor.2013.03.073
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Purpose. Show our experience in accelerated partial breast irradiation (APBI) with HDR brachytherapy, implementation and one
year of treatment, in a selected group of patients with early-stage breast cancer.
Methods and materials. From August 2011 to November 2012, six selected patients with T1 N0, Grade 1–2 ductal breast cancer,
were treated after breast-conserving surgery, with high-dose-rate (HDR) multicatheter brachytherapy. Inclusion criteria were the
most restrictive of ASTRO and ESTRO recommendations. In all cases we performed a CT scan, in which we perform a virtual
dosimetry preimplantation subsequently reproduce the ﬁnal implant. The clinical target volume was drawn with a 1-cm margin
around the surgical clips or seroma, protecting skin and chest wall. All the regions of interest were contoured according to the
International Commission on Radiation Units and Measurements reports 50 and 62 recommendations. Prescribed dose to the
PTV was 34Gy in 3.4Gy fractions in 5 days.
Results. The average size of the PTV was 63.7 cc (50–120), with V100% mean 94.5% V150% mean 26.94 cc, V200% mean 10.69 cc and
D90 average was 105%. DHI (Dosie Homogenity Index) average was 0.62, and COIN (Conformatin Index) average was 0.66. Acute
toxicity: pain in 2 patient, and hematoma in 2 patients. Acute Radiodermitis was not observed. Late toxicity: ﬁbrosis grade1
was observed in 2 patients, and grade 2 in another patient. Slight pigmentation is observed in 2 patients. There have been no
locoregional recurrences or metastases. The aesthetic result was good or very good en 5 patients, and excellent in one.
http://dx.doi.org/10.1016/j.rpor.2013.03.074
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Introduction. Previous studies have demonstrated increased cardiac mortality and morbidity after left-sided breast irradiation.
Different technologies have been developed to minimize this problem. We have analyzed the dosimetry and dose-volume his-
tograms of ten patients diagnosedwith left side breast cancer, stage IA and IB; forwhomweplanned the same two-ﬁeld tangential
treatment with and without active breathing control (ABC) technique.
Objective. To demonstrate dose reduction to left anterior descending coronary artery (LAD) and heart using moderate deep
inspiration breath hold (mDIBH) with ABC.
Methods. Patients underwent scanning free breathing (FB) and then employing active breathing control technique. The mDIBH
treatments were compared with the standard free-breathing for each patient. Dosimetric parameters evaluated: mean heart
dose, heart V50%, mean LAD dose, maximal dose to 0.2 cm3 of the LAD, mean left lung dose and percentage of lung receiving
≥20Gy.Results. The heart V50 decreased to 0% in 8 of 10, the decreasing average was 95%, from a 1.58% of the heart receiving
more than 50Gy in the FB plan to a media of 0.08% with mDIBH (p:0.012); overall, the mean dose to the heart was reduced from
1.989Gy to 0.98Gy (p:0.005), a relative reduction of 50.4%. The mean dose to the LAD was reduced from 14.06Gy with FB to 3.55Gy
using mDIBH (p:0.008), relative reduction of 74.75%. The maximal dose to 0.2 cm3 was reduced from 21.69Gy to 6.36Gy, (p: 0.008),
a reduction of 70.67%. Regarding the left lung, this technique does not seem to show a clear improvement, nor in the V20, nor
in the mean dose.Conclusion. MDIBH with ABC signiﬁcantly reduces heart and LADC doses, what can potentially reduce cardiac
risks. However, lung doses do not show a homogeneous decrease.
http://dx.doi.org/10.1016/j.rpor.2013.03.075
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Introduction. Coronary artery disease is the leading cause of mortality among RT-treated survivors of breast cancer. Signiﬁcantly
increases the risk of 2–3 times compared to the untreated population. The median time to onset varies between 6 and 10 years
